|
ATCC
male prostate cancer cell line vcap Male Prostate Cancer Cell Line Vcap, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/male prostate cancer cell line vcap/product/ATCC Average 99 stars, based on 1 article reviews
male prostate cancer cell line vcap - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
vcap cell line Vcap Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/vcap cell line/product/ATCC Average 99 stars, based on 1 article reviews
vcap cell line - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
vcap parental cell line Vcap Parental Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/vcap parental cell line/product/ATCC Average 99 stars, based on 1 article reviews
vcap parental cell line - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
vcap cell lines ![]() Vcap Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/vcap cell lines/product/ATCC Average 99 stars, based on 1 article reviews
vcap cell lines - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
human prostate cell line vcap ![]() Human Prostate Cell Line Vcap, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human prostate cell line vcap/product/ATCC Average 99 stars, based on 1 article reviews
human prostate cell line vcap - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
prostate cancer cell lines lncap ![]() Prostate Cancer Cell Lines Lncap, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/prostate cancer cell lines lncap/product/ATCC Average 99 stars, based on 1 article reviews
prostate cancer cell lines lncap - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
tumor cell line vcap fgc ![]() Tumor Cell Line Vcap Fgc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/tumor cell line vcap fgc/product/ATCC Average 99 stars, based on 1 article reviews
tumor cell line vcap fgc - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
cell lines hek293t atcc crl 3216tm lncap atcc crl 1740 tm 22rv1 atcc crl 2505 c4 2 atcc crl 3314 vcap atcc crl 2876 pc 3 atcc crl ![]() Cell Lines Hek293t Atcc Crl 3216tm Lncap Atcc Crl 1740 Tm 22rv1 Atcc Crl 2505 C4 2 Atcc Crl 3314 Vcap Atcc Crl 2876 Pc 3 Atcc Crl, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cell lines hek293t atcc crl 3216tm lncap atcc crl 1740 tm 22rv1 atcc crl 2505 c4 2 atcc crl 3314 vcap atcc crl 2876 pc 3 atcc crl/product/ATCC Average 99 stars, based on 1 article reviews
cell lines hek293t atcc crl 3216tm lncap atcc crl 1740 tm 22rv1 atcc crl 2505 c4 2 atcc crl 3314 vcap atcc crl 2876 pc 3 atcc crl - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
Journal: Cancer research
Article Title: Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
doi: 10.1158/0008-5472.CAN-25-1532
Figure Lengend Snippet: A. Tumor size over time of SKCaP-1R patient-derived xenograft tumors growing untreated (Control) or treated with supraphysiological androgen (SPA; testosterone cypionate subcutaneous pellet). B. Principal component analysis with 95% confidence ellipses of metabolite abundance in tumors from (A). C. Volcano plot displaying change in metabolite abundance in SKCaP-1R tumors treated with SPA versus Control from (A). D. Polyamine synthesis pathway schematic displaying metabolites altered in abundance by SPA in tumors from (A). E. Isotope tracing schematic. Cells were treated with either vehicle control (VEH; EtOH 0.1%) or SPA (R1881 10nM) in media containing either uniformly-labeled 13 C-arginine or 13 C-putrescine Metabolites were extracted at 24 hours. F-G. Contribution of polyamine synthesis pathway metabolites from arginine (F) or putrescine (G) in LNCaP and VCaP cells treated with VEH or SPA as per experimental design of (E). N=3 independent experiments. P values by unpaired 2-tailed t test.
Article Snippet: LNCaP and
Techniques: Derivative Assay, Control, Labeling
Journal: Cancer research
Article Title: Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
doi: 10.1158/0008-5472.CAN-25-1532
Figure Lengend Snippet: A. The top 3 tracks display AR ChIP-seq of VCaP cells treated with vehicle control, supraphysiological androgen (SPA; DHT 10nM), or SPA and enzalutamide (ENZA; 10uM) for 12 hours. Data reanalyzed from Asangani et al, 2014( 35 ). Lower tracks display AR ChIP-seq of 7 histologically normal prostate samples and 13 local prostate cancer samples. Data reanalyzed from Pomerantz et al, 2015( 36 ). B. Schematic depicting dCas9-KRAB-mediated blockade of AR binding. C. Protein expression of ODC by western blot of LNCaP cells expressing dCas9-KRAB and indicated sgRNA treated with vehicle control (V) or supraphysiological androgen (S; R1881 10nM) for 24 hours. Vinculin is used as a loading control. Total ODC quantification and ODC fold-change (FC) by SPA of n = 3 independent experiments are displayed below with p values by unpaired 2-tailed t test.
Article Snippet: LNCaP and
Techniques: Binding Assay, ChIP-sequencing, Control, Expressing, Western Blot
Journal: Cancer research
Article Title: Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
doi: 10.1158/0008-5472.CAN-25-1532
Figure Lengend Snippet: A. MYC ChIP-seq in VCaP cells treated with vehicle control or supraphysiological androgen (SPA; DHT 10nM) for 4 hours. Data reanalyzed from Guo et al, 2021( 40 ). B. Change in indicated transcript expression by RNAseq in VCaP cells with control knock-down or MYC knock-down by siRNA. Data reanalyzed from Guo et al, 2021( 40 ). C . Expression of indicated proteins in LNCaP cells expressing empty vector (EV) or MYC (MYC) treated with vehicle control (V; EtOH 0.1%) or SPA (S; R1881 10nM) for 96 hours. Vinculin is used as a loading control. Representative blot of n=2 experiments. D. Change in indicated transcript expression by RNAseq in cells treated as per C. E. A comparison of change of individual RNA transcript abundance by SPA in LNCaP-EV cells versus LNCaP-MYC cells. The line of best fit (dotted red) has a shallower slope than the line of unity (solid blue), indicating that many transcripts have reduced change by SPA in LNCaP-MYC cells. F. Schematic highlighting that the inhibition of MYC by SPA can function as an amplifying circuit to further increase expression of ODC1 , AMD1 , and KLK3 by SPA. P values by unpaired 2-tailed t test in B and D.
Article Snippet: LNCaP and
Techniques: Expressing, ChIP-sequencing, Control, Knockdown, Plasmid Preparation, Comparison, Inhibition
Journal: Cancer research
Article Title: Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer
doi: 10.1158/0008-5472.CAN-25-1532
Figure Lengend Snippet: A . Principal component analysis of RNAseq of LNCaP cells treated with vehicle control (VEH; EtOH 0.1%), supraphysiological androgen (SPA, R1881 10nM), DFMO (5mM), DFMO and putrescine (PUT; 100uM), DFMO and SPA (SD), and DFMO and SPA and PUT for 96 hours. B-C. Volcano plot displaying change in transcript abundance in LNCaP cells treated with DFMO and SPA (SD) versus VEH (B) or versus SPA (C) as per A. D. RNA and protein expression of MYC of LNCaP and VCaP cells with indicated treatments for 96 hours. MYC RNA expression was normalized to ACTB and MYC protein expression was normalized to vinculin. P values by unpaired 2-tailed t test. E. Volcano plot displaying normalized enrichment scores of HALLMARK gene sets in LNCaP cells treated with DFMO and SPA versus VEH as per (A). F. Abundance of proteins with monomethyl arginine and H4-SDMA in LNCaP and VCaP cells with indicated treatments for 96 hours. G . Protein expression of MYC and AMD1 by western blot in LNCaP and VCaP cells treated with indicated treatments, including spermidine (SPD; 100uM), spermine (SPM; 100uM), toluenesulfonic acid (TSA; 200uM), S-adenosyl-methionine-toluenesulfonic acid (TSA-SAM; 25uM, 50uM, 100uM, 200uM), SAM486 (2uM), and aminoguanidine (1mM) as indicated, for 96 hours. H. Schematic displaying effects of SPA and DFMO combination treatment.. Vinculin is used as a loading control in F and H, where blots are representative of n = 2 or 3 experiments.
Article Snippet: LNCaP and
Techniques: Inhibition, Control, Expressing, RNA Expression, Western Blot